Latest Chemomab Therapeutics News & Updates

See the latest news and media coverage for Chemomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Chemomab Therapeutics (Chemomab)

Clinical-stage biotechnology company developing fibro-inflammatory therapeutics

chemomab.com

Headquarters: Tel Aviv, Israel
Founded year: 2011
Company type: Public company
Number of employees: 20–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Chemomab Therapeutics (Chemomab)

In short: Chemomab agreed to merge with Scipher Medicine to develop AI-powered therapies while advancing its lead candidate, nebokitug, into Phase 3.

Company announcements

July 8 Chemomab

Chemomab announces merger agreement with Scipher Medicine to advance nebokitug

The combined company plans an AI-powered Phase 2 trial in rheumatoid arthritis using Scipher's platform.

May 14 Chemomab

Chemomab announced first quarter 2026 financial results

The company reported net loss of $1.8 million and provided updates on nebokitug clinical progress.

May 5 Chemomab

Chemomab announces nebokitug proteomic study results

Dr. Parvez Mantry presented dose-dependent reductions in inflammatory signatures at Digestive Disease Week. Data suggest benefits for PSC patients with IBD. Q1 2026 results release on May 14.

March 19 Chemomab

Chemomab announces 2025 year-end financial results

Reports $10.4M cash, reduced R&D expenses, net loss of $9.0M. Highlights FDA alignment on Phase 3 PSC trial for nebokitug and strategic partner discussions.

Media coverage

July 8 The Globe and Mail

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI...

June 2 TipRanks

Top Executive’s Sudden Stock Move Sends Chemomab Investors Scrambling - TipRanks.com

New insider activity at Chemomab Therapeutics ( ($CMMB) ) has taken place on June 1, 2026. Chemomab Therapeutics has reported an insider transaction by its...

May 14 Markets Insider

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary ...

March 23 Stock Titan

Chemomab Therapeutics (CMMB) flags going-concern risk and reliance on nebokitug

Chemomab Therapeutics, a clinical-stage Israeli biopharma company, filed its annual report outlining its business, key risks and financial position. The company focuses on nebokitug (CM-101...

Never miss news about Chemomab

Track Chemomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Chemomab competitors & trending companies

Browse news for competitors to Chemomab and other trending companies.